Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

GNI In-licenses Hepatitis Drug from EpiCept

publication date: Jul 22, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

GNI has in-licensed a late-stage hepatitis drug from EpiCept. GNI now owns the rights for EP1013 in Asia, Australia and New Zealand, while EpiCept retains control of the drug in the rest of the world. GNI, which is based in Japan, will put its wholly-owned China subsidiary, Shanghai Genomics, in charge of the pre-IND and clinical development of EP1013. GNI has another hepatitis drug already in development, F351, for liver fibrosis. More details...

Stock Symbols: (TOKYO: 2160) (NSDQ: EPCT)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...